WHO vaccine-preventable diseases: monitoring system. 2018 global summary

Last updated 15-Jul-2018 (data as of 15-Jul-2018)
Next overall update Winter 2018
EPI mother and child logo         
Select a country

Development status: Developed economy GNI / capita (US$): 31'0201 Infant (under 12 months) mortality rate: 32
GDP / capita (US$): 39'8171 Child (under 5 years) mortality rate: 32

Population data in thousands3

  2017  2016  2015  2014  2013  2000  1990  1980 
Total population 59'360  59'430  59'504  59'586  59'668  57'294  57'127  56'419 
Births 485  490  495  502  510  534  559  670 
Surviving infants 484  489  494  501  509  531  555  660 
Pop. less than 5 years 2'448  2'482  2'554  2'607  2'671  2'637  2'822  3'570 
Pop. less than 15 years 8'024  8'087  8'168  8'223  8'279  8'208  9'408  12'393 
Female 15-49 years 12'250  12'441  12'630  12'843  13'052  13'916  14'372  13'707 

Number of reported cases

(Click for retrospective incidence data for Italy)
Diphtheria
ChartChart
  30 
Japanese encephalitis
 
Measles
ChartChart ChartChart
  4'042  159  1'457  5'223  27'452 
Mumps
ChartChart
  508  37'669 
Pertussis
ChartChart
  510  2'543  16'992  16'643 
Polio*
ChartChart
 
Rubella
ChartChart
  31  16  2'605 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
 
Tetanus (total)**
ChartChart
  33  47  98  123  176 
Yellow fever
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For disaggregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Italy)
Vaccine year result method % card seen                                                
BCG         
DTP1         
DTP3 2007  97       94  93  95  96  87  80 
DTP4          88 
IPV1         
HepB_BD         
HepB3 2007  97       94  93  95  96  94 
Hib3 2007  96       94  93  94  95  55 
JapEnc         
MCV1          92  85  87  90  74  43 
MCV2          86  83  83  84 
MenA         
PCV1         
PCV2         
PCV3 2007  55       91  89  87  87 
Pol3 2007  97       94  93  95  96  97  98 
Rota1         
RotaC 2007       13 
RCV1          92  85  87  90  74 
TT2plus         
PAB         
VAD1         
YFV         
* indicates the country reported above 100% coverage.

  Next update: Mid July 2019

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Italy)
BCG
 
DTP1
ChartChart
  98  98  97  98  98  95  94 
DTP3
ChartChart
  94  94  93  95  96  87  83 
HepB3
ChartChart
  94  94  93  95  96  94 
HepB_BD
 
Hib3
ChartChart
  94  94  93  94  95  55 
MCV1
ChartChart
  92  89  85  87  90  74  43 
MCV2
ChartChart
  86  85  83  83  84 
PCV3
ChartChart
  91  90  89  87  87 
Pol3
  94  94  93  95  96  97  98 
RCV1
ChartChart
  92  89  85  87  90  74  43 
RotaC
ChartChart
  13 

Click for WHO-UNICEF coverage estimates data for PAB time series.

Number of districts in the country 21  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
 
   
/
|
|
\
Greater or equal to 90%
From 80 to 89%
From 50 to 79%
Less than 50%
Proportion of districts
not reporting DTP3 coverage
100
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2017 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG Yes health workers at high risk
DTaP 2, 4, 11 months; 5-6, 14-18 years; Yes
DTaPHep 3, 5-6, 11-13 months; Yes
DTaPHepB 2, 4, 11 months; 5-6, 14-18 years; 1
DTaPHepBIPV 2, 4, 11 months; 5-6, 14-18 years; Yes
DTaPHepIPV 3, 5-6, 11-13 months; Yes
DTaPHib 2, 4, 11 months; 5-6, 14-18 years; Yes
DTaPHibHepB 2, 4, 11 months; 5-6, 14-18 years; Yes
DTaPHibHepBIPV 2, 4, 11 months; 5-6, 14-18 years; Yes
DTaPHibHepIPV 3, 5-6, 11-13 months; Yes
DTaPHibIPV 2, 4, 11 months; 5-6, 14-18 years; Yes
DTaPIPV 2, 4, 11 months; 5-6, 14-18 years; Yes
HepA_Adult 1st contact, +6-12 months; Yes recommended for persons with clinical, behavioral or occupational risks
HepA_Pediatric 13-14, 24 months; No endemic region
HepB_Adult 1st contact; +1, +6 months; Yes recommended for persons with clinical, behavioral or occupational risks
HepB_Pediatric 2, 4, 11 months; Yes
HPV 11 years; +6 months; Yes females and males; and MSM
Influenza_Adult >65 years; Yes and adults with chronic illness, pregnant women, health care workers, residents living in long-term facilities, other risk groups
Influenza_Pediatric Yes children with chronic illness
IPV 2, 4, 11 months; 5-6, 14-18 years; Yes
MenACWY-135 conj 11-18 months; Yes
MenC_conj 13-15 months; Yes and subjects of all ages with clinical indications
MMR 13-15 months, 5-6 years; Yes and susceptible teens and adults; recommended to persons with occupational risks
MMRV 13-15 months; 5-6 years; Yes and recommended to persons with occupational risks
Pneumo_conj 2, 4, 11 months; Yes and subjects of all ages with clinical indications
Rotavirus 6 weeks-8 months Yes the number of doses (2 or 3) depends on the vaccine's type
Td 11-18 years; Yes every 10 years
Tdap 5-6, 11-18 years; Yes every 10 years
TdaPIPV 5-6, 11-18 years; Yes
TdIPV 11-18 years; Yes
Varicella 13-15 months; 5-6 years; Yes and recommended to persons with occupational risks

Immunizaton indicators

Indicator Expected answer 2017  2016  2015  2014  2013  2012  2011 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  Yes      Yes  Yes 
What years does the MYP cover? number 2017-2019  2012-2014 and 2017-2019  2016-2018      2012-2014  2012-2014 
Nº of districts with microplans that include activities to raise immunization coverage number 20  21  21      16   

System performance

Total Nº districts in country number 21  21  21      21  21 
Nº districts with DTP3 coverage >=80% number           14  14 
% of districts with DTP3 coverage >=80% From 0 to 100%           67  67 
Nº districts with measles (MCV1) coverage >=95% number          
% of districts with MCV1 coverage >=95% From 0 to 100%          

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes  Yes      No  Yes 
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes      Yes   

Finance

% of Immunization expenditure financed, using Government funds? From 0 to 100%   100        100   

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  No  No      No  No 

Sources

 1  "The 2018 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2018, data for 2016
 3  "United Nations, Population Division. The World Population Prospects - the 2017 revision". New York, 2017.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.